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Abstract
Background: The control of malaria in schools is receiving increasing attention, but there remains currently no
consensus as to the optimal intervention strategy. This paper analyses the costs of intermittent screening and
treatment (IST) of malaria in schools, implemented as part of a cluster-randomized controlled trial on the Kenyan
coast.
Methods: Financial and economic costs were estimated using an ingredients approach whereby all resources
required in the delivery of IST are quantified and valued. Sensitivity analysis was conducted to investigate how
programme variation affects costs and to identify potential cost savings in the future implementation of IST.
Results: The estimated financial cost of IST per child screened is US$ 6.61 (economic cost US$ 6.24). Key
contributors to cost were salary costs (36%) and malaria rapid diagnostic tests (RDT) (22%). Almost half (47%) of the
intervention cost comprises redeployment of existing resources including health worker time and use of hospital
vehicles. Sensitivity analysis identified changes to intervention delivery that can reduce programme costs by 40%,
including use of alternative RDTs and removal of supervised treatment. Cost-effectiveness is also likely to be highly
sensitive to the proportion of children found to be RDT-positive.
Conclusion: In the current context, school-based IST is a relatively expensive malaria intervention, but reducing the
complexity of delivery can result in considerable savings in the cost of intervention.
(Costs are reported in US$ 2010).
Background
There is a growing appreciation that malaria not only
impacts on the health of infected individuals but also has
broader social and economic consequences [1,2]. Recent
evidence suggests that non-severe malaria can affect the
cognition, attention and ultimately educational achieve-
ment of school children [3-7]. Reaching this population is
most effectively achieved via the school infrastructure, and
with increasing enrolment in schools by African school-
age children [8], schools provide a natural access point for
malaria control among this age group. Notwithstanding
this potential, the optimal approach to controlling malaria
in schools remains unclear [4,9]. Recent studies in Africa
have demonstrated the potential of intermittent preventa-
tive treatment (IPT) - the administration of curative doses
of anti-malarial treatment at predefined intervals regard-
less of infection status - in reducing malaria parasitaemia,
clinical disease and anaemia and improving cognitive
performance [3,10,11]. Moreover, modelling work demon-
strates that IPT administered among school-age children
can also help reduce malaria transmission in the wider
community, particularly in areas of low to moderate trans-
mission [12]. However, recent changes in national drug
policies in many African countries preclude the use of
sulphadoxine-pyrimethamine and amodiaquine, some of
the drugs previously used in IPT, thereby limiting its
potential implementation.
An alternative school-based malaria control strategy is
intermittent screening and treatment (IST), using rapid
diagnostic tests (RDTs) to screen and treat asymptomatic
children. Recent studies in Ghana found IST in pregnant
women to be equally efficacious as IPT [13] and accepta-
ble to patients [14]. The present analysis examines the
costs of IST of school children in two districts in coastal
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Kenya as part of an ongoing trial investigating the impact
IST has on the health and education of school children
[15]. The analysis explores how variation in the design of
the intervention, including different component prices,
affects programme cost.
Methods
Description of the IST trial
A factorial, cluster randomized trial is currently investigat-
ing the impact of school-based malaria control and
enhanced literacy instruction on the health and educa-
tional achievement of school children in Kenya. The study
design and description of the intervention are detailed
elsewhere [15]. In brief, the trial is being implemented,
2010-2012, in 101 primary schools on the coast of Kenya
where continuous precipitation supports moderately
intense malaria transmission (predominantly Plasmodium
falciparum). Typically, there are two seasonal peaks in
malaria cases reflecting the bimodal rainfall pattern; the
heaviest rainfall typically occurring between April and
June and a smaller peak in October and November each
year. Under nutrition, especially anaemia, is common [16].
In terms of education, the area is one of the poorest
performing in Kenya, having the lowest mean national
examination scores since 2005 [17].
The interventions being evaluated are (i) intermittent
screening and treatment of malaria in schools by public
health workers and (ii) training workshops and support
for teachers to promote explicit and systematic literacy
instruction (not evaluated here). The primary outcomes
are educational achievement and anaemia. Secondary
outcomes include malaria parasitaemia, school atten-
dance, sustained attention and other cognition abilities.
Randomly selected children from classes 1 and 5 are
included in the evaluation. Baseline health and education
surveys were conducted in intervention and control
schools between January and March 2010, with 12 and
24-month follow-up surveys scheduled.
Intermittent screening and treatment (IST)
Each school term, all children are tested for malaria using
a RDT. The RDT used is a ParaCheck-Pf device (Orchid
Biomedical Systems, Goa, India) which is able to detect
P. falciparum and other (unspecified) Plasmodium spe-
cies. Children (with or without malaria symptoms) found
to be RDT-positive are treated with artemether-lumefan-
trine, AL (Coartem®, Novartis), an artemisinin-based
combination therapy. Testing and treatment is adminis-
tered by district health workers and supported by the
Division of Malaria Control (DoMC), Ministry of Public
Health and Sanitation (MoPHS).
On day 1, children are screened by a laboratory techni-
cian using a RDT. Those children found to be RDT-posi-
tive are given milk and bread and then given the first dose
of AL. Parents or older siblings of children are called and
a nurse explains that their child is infected with malaria
parasites and requires treatment (assuming they are not
already taking medication). The parents/older siblings are
given the second dose of AL and told that this should be
taken in the evening with food. On day 2, the nurse
returns to the school, gives the third AL dose to children
and provides the parent/older sibling with the fourth dose.
Children absent from school are followed up at their
home and provided with the doses. On day 3, the proce-
dures are the same as day 2. During follow-up visits nurses
monitor for potential side effects of treatment.
Costing
The analysis is undertaken from the perspective of the
Government of Kenya, as a public service provider. Only
costs to the provider are included as costs to the patient
of accessing the intervention are likely to be low since it
is delivered in schools and there is no fee to receive the
intervention. The costs of accessing IPT have previously
been considered negligible on the same basis [18,19]. The
comparison (null) for this evaluation is no intervention.
The total economic cost is calculated based on an initial
5 year programme implementation. The decreased value
placed on future costs and annualization of capital costs
is calculated using a 3% discount rate, in line with WHO
recommendations [20]. The financial costs are the unad-
justed funds required to finance the intervention and the
economic cost reflects the total resource burden, taking
into account the value of donated goods or unpaid
workers.
Programme costing was guided by a three-step process:
resource identification, resource measurement and
resource valuation. In this process, relevant unit costs
were collected according to an ingredients based
approach [21], the quantity or usage of each ingredient
was determined and combined with cost information to
produce a monetary valuation of total resources used, or
economic cost. Costs were separated into those that
required new funds, such as the purchase of additional
RDTs and antimalarials, and those that involved the
redeployment of existing resources, including use of
health workers who would otherwise have duties at the
local health facility.
Data collection was undertaken in 2010, with unit costs
established from the project accounting system and from
interviews with purchasing officers. Where information
was unavailable or unrepresentative, unit costs were
sourced from the Ministry of Public Health and Sanita-
tion (MoPHS) or wholesale market prices. Ingredient
usage was established from direct observation of the
intervention, interviews with trial co-ordinators, from
health worker time sheets and driver mileage survey. The
majority of costs were collected in Kenyan Shillings
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(KES) and then converted to US$ using the average
exchange rate from the preceding 12 months (01.08.09 to
31.07.10): US$ 1 = KES 79.9 [22]. Costs derived from
other years were inflated or deflated to 2010, using a
compound inflation factor based on the year by year con-
sumer price index [23]. The World Health Organization
CHOosing Interventions that are Cost-Effective (WHO
CHOICE) [24] was used to determine the country speci-
fic item lifespan of capital items: vehicle 8 years, personal
computer 10 years, printer 10 years. Costs relating to
activities solely for research purposes were excluded. To
account for resource waste through faulty goods, mis-
handling or accidents, a wastage factor of 10% was
applied to all relevant items.
Intervention costs were grouped by resource type
including: personnel; transport; field equipment; and
health facility costs. In addition, costs were broken down
by the various components or activities of the intervention
including: community sensitisation; screening day; treat-
ment days; administration; training and monitoring. Com-
munity sensitisation involves a meeting with parents and
teachers at every school to describe the intervention and
answer questions. This occurs once and comprises the set-
up costs of the intervention, thus costs were annualized
across the five-year programme. Screening day is the first
day of the intervention, children are screened and treat-
ment is started. Days two and three are treatment days
where a nurse returns to the school to supervise the morn-
ing treatment and deliver the evening dose. Administra-
tion includes coordinator time, office use and the cost of
distributing significant extra quantities of RDTs and anti-
malarials to district hospitals. Training on the intervention
delivery and a refresher of relevant clinical practice is
given to all staff at every screening round. Monitoring of
intervention delivery is undertaken by supervising health
officers joining two intervention teams for observation at
every round. A summary of intervention components is
found in Table 1. Activity cost is cross-tabulated against
resource category to provide a concise but detailed
account of cost distribution. Unit costs are provided in the
supplementary information (Additional file 1).
Sensitivity analysis
Univariate sensitivity analysis was conducted to deter-
mine how sensitive costs are to variation in input para-
meters, including commodity prices, the design of the
delivery strategy, and evaluation methodology. Results
are displayed graphically using a tornado diagram. For
anti-malarials and RDTs, the highest and lowest prices of
equivalents available in Kenya were chosen. Other vari-
ables examined include salary levels (± 20%); discount
rate (0%, 5%), and wastage factor (0%, 20%). To investi-
gate the marginal cost of supervising treatment, health
worker attendance on days 2 and 3 were removed, with
parents/older siblings being given a full treatment course
and instructions on how to administer treatment on the
screening day. The second intervention change was the
removal of technicians from the screening teams, with
nurses from local health facilities carrying out RDT test-
ing. The current estimates for time spent at schools
includes preparation of blood slides and collection of
research information. For the sensitivity analysis is it esti-
mated that nurses could carry implement IST without a
technician under non-research conditions.
A final parameter investigated was the prevalence of
Plasmodium falciparum in the target population, a factor
that will determine the quantity of anti-malarial treat-
ments used. Simulations using bespoke scripting in Micro-
soft Excel (2007) were performed, whereby variation in
prevalence of infection was simulated through repeated
sampling of programme cost at random prevalences. One
thousand repetitions were performed in order to cover the
full prevalence range. The cost per child screened and cost
per child treated are plotted to present variation in pro-
gramme cost and cost-effectiveness (the number of chil-
dren treated is a proxy measure of effect).
Ethical and scientific approval for the present study is
provided as part of the wider trial by the Kenya Medical
Research Institute and National Ethics Review Commit-
tee (SSC No. 1543), the London School of Hygiene and
Tropical Medicine (LSHTM) Ethics Committee (5503),
and the Harvard University Committee on the Use of
Human Subjects in Research (F17578-101). Sponsorship
Table 1 Components of the intermittent screening and treatment in school children in coastal Kenya
1. Community
sensitisation
Sensitization consisted of a meeting with parents and teachers at every school to describe the intervention and answer
questions. It occurs once and comprises the set-up costs of the intervention, thus costs are annualized across the five-year
programme.
2. Training A half-day training on the intervention delivery and a refresher of relevant clinical practice is given to all staff at every
screening round.
3. Screening day A mobile health team travels to the school. Children are screened by a laboratory technician using a RDT and those found
to be RDT-positive are given milk and bread and the first dose of treatment. The evening dose is given to the child or if
the child is too young to take responsibility the parents or older sibling are called.
4. Treatment
Follow-up
On days two and three a nurse returns to the school to supervise the morning treatment dose and deliver the evening
dose.
5. Monitoring Supervising health officers join two intervention teams for observation at each round.
6. Administration This includes coordinator time, office use and the cost of distributing significant extra quantities of RDTs and anti-malarials
to district hospitals.
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and insurance is provided by the LSHTM’s Clinical
Trials Sub-Committee (QA225).
Results
The total financial cost of providing a five-year pro-
gramme of malaria screening and treatment to 3,685 chil-
dren is estimated to be US$ 365,104 or US$ 6.61 per
child screened. The economic costs of the programme
are US$ 69,062 per year, US$ 6.24 per child screened or
US$ 18.72 per child per year. Table 2 provides a break-
down of financial and economic costs. The largest single
contributors to cost are salaries (36%) and RDTs (22%).
Almost half (47%) of the intervention cost comprises
redeployment of existing resources including health
worker time and use of hospital vehicles. The new funds
required are largely due to RDTs and other consumables,
their distribution to local facilities and staff per diems.
Table 3 presents the resource costs cross-tabulated
against the intervention activities and shows that the
majority of the costs are spent on screening (52%), then
treatment follow-up (21%) and intervention administra-
tion (20%). Data from the health worker time surveys
indicates that daily travel to and from the schools during
screening took on average 3 hours 20 minutes or 47% of
total time. Undertaking the screening and providing
treatment took 3 hours 16 minutes (45%), with prepara-
tion in the schools taking 36 minutes (8%).
Sensitivity analysis
The parameters included in the sensitivity analysis and
the change in cost per child screened are detailed in
Table 4 and displayed graphically in Figure 1. Choice of
RDT had a large impact on overall costs (12% reduction
or 33% increase), whereas drug choice had negligible
impact. The biggest cost saving was removing the treat-
ment follow-up (21%), whilst not including technicians in
the screening teams reduced costs by 7%. Other varia-
tions altered costs by less than 10%. This analysis identi-
fies three intervention alterations which together may be
expected to reduce total cost by 40% without significantly
Table 2 Financial and economic costs of malaria intermittent screening and treatment in schools in coastal Kenya by
resource category (US$ 2010)
Financial Cost1 Annual Economic Cost Economic cost per child screened Cost Profile (%)6
Resource New funds Existing resources Total
Personnel:
Salaries - 132,516 132,516 25,077 2.27 36
Per Diems 22,852 - 22,852 4,357 0.39 6
22,852 132,516 155,368 29,434 2.66 43
Transport:
Vehicle - 17,387 17,387 3,292 0.30 5
Fuel 11,771 - 11,771 2,229 0.20 3
Servicing - 16,884 16,884 3,197 0.29 5
Distribution2 33,104 - 33,104 6,246 0.57 9
44,875 34,271 79,146 14,965 1.35 22
Facility:
Rent3 - 5,016 5,016 957 0.09 1
Other4 2,761 - 2,761 534 0.05 1
2,761 5,016 7,777 1,490 0.13 2
Field Equipment:
RDTs 80,650 - 80,650 15,217 1.38 22
Anti-malarials 9,919 - 9,919 1,872 0.17 3
Other5 32,243 - 32,243 6,084 0.55 9
122,813 - 122,813 23,173 2.10 34
TOTAL 193,301 171,803 365,104 69,062 6.24 100
% 53 47
1 Financial costs are the undiscounted direct monetary costs for the programme over five years.
2 Cost of transporting extra RDTs and anti-malarials to the district hospital.
3 Includes utilities and furniture.
4 Includes office consumables and computer equipment.
5 Includes blood lancets, cotton wool, gauze roll, gloves, paper towels, disinfectant dispenser, thermometer, biscuit packs, milk cartons, bottled water,
paracetamol, pencils, erasers, sharpeners, masking tape, garbage bag, marker pens, scissors, dust bin, triple timers, weighing scales and mobile phone credit.
6 Applies to both financial and economic costs.
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altering the fidelity of delivery: (i) using a cheaper RDT
brand; (ii) removing directly observed treatment follow-
up; and (iii) removing technicians from health teams and
allowing nurses to carry out RDTs.
Figure 2 shows the relationship between the preva-
lence of P. falciparum infection (as based on RDT
results) and the cost per child screened and cost per
RDT-positive child treated. As RDT-positivity increases,
the cost per child screened increases in a linear fashion
since more anti-malarials are required. However, as pre-
valence of infection decreases the cost per child treated
rises exponentially.
Discussion
The current analysis estimates that the financial cost of
IST is US$ 6.61 per child screened. The economic cost
is US$ 6.24 although the difference is largely due to dis-
counting of costs incurred in the future. The largest cost
components were RDTs and salaries. Almost half (47%) of
the costs comprised of the redeployment of existing
resources including health worker time and use of hospital
vehicles. While this may reduce the new funds required to
finance the intervention it also highlights the potential for
additional strain to be placed on existing resources,
depending on the current working capacity. Sensitivity
Table 3 The costs of malaria intermittent screening and treatment in schools in coastal Kenya by resource category
and intervention activity (US$ 2010)
Resource
Activity Personnel Transport Facility Field Equipment TOTAL %
Sensitisation 872 231 166 - 1,270 2
Training 943 - 44 17 1,003 1
Screening 12,642 2994 - 20,399 36,035 52
Follow-Up 6,317 5,494 - 2,757 14,568 21
Monitoring 2,126 - 132 - 2,258 3
Administration 6,535 6,246 1,148 - 13,929 20
TOTAL 29,434 14,965 1,490 23,173 69,062 100
% 43 22 2 34 100
Table 4 Sensitivity analysis of the costs of malaria intermittent screening and treatment in schools in coastal Kenya
Parameter Parameter Baseline Value Variation and Justification Cost Per Child
Screened
(% Change)
Baseline Result: $6.24
Lower
Value
Upper
Value
RDT Paracheck: $1.32 First Response: $0.61
NOW Malaria: $3.21
The cheapest and most expensive high performing alternatives considered by
the Kenyan government.
$5.52
(-12%)
$8.31
(+33%)
Anti-malarial AL: $0.31 - 1.23 depending on
child weight
AQ + SP: $0.125
DP: $0.741
Dihydroartemisinin Piperaquine (DP) is an alternative ACT while Amodiaquine
Sulphadoxine-Pyrimethamine (AQ + SP) is a cheap alternative that might be
used in an area where SP is still effective.
$6.12
(-2%)
$6.24
(< 1%)
Treatment
Follow Up
Treatment follow up carried out
by nurses as described
Unsupervised treatment has been shown to be similarly efficacious [37,38] and
national guidelines permit unsupervised treatment [39]. Alternative treatment
may also reduce follow up requirements.
$4.95
(-21%)
-
Health Team
Personnel
Technicians used by trial to
carry out RDT and blood slide.
Nurses implement IST without technicians.
Personnel may be reduced by removing research tasks such as taking blood
slides and anthropometry.
$5.79
(-7%)
-
Salaries Midpoint of relevant pay scales. ± 20%
Salaries are likely to vary by region or over time
$5.80
(-7%)
$6.73
(+8%)
Discount
Rate
3%
Recommended by
WHO [20]
0% and 5%
0% reflects un adjusted programme costs. Some argue that time preferences for
delay of costs are not necessarily rational and should not be included in
decision-making. 5% represents a greater time preference, argued by some to be
more relevant to developing country contexts.
$6.63
(+6%)
$6.04
(-3%)
Wastage 10% 0% and 20%
No empirical evidence. Based on literature precedent.
$6.06
(-3%)
$6.47
(+4%)
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analysis highlighted that changes to the delivery strategy,
such as using different RDTs, removing treatment follow-
up and only including nurses in the screening team, can
reduce overall costs by 40%, increasing the affordability of
the intervention.
Although IST is principally a strategy of treatment
rather than prevention of malaria, it can be compared to
preventive interventions such as IPT in that it seeks to
prevent malaria associated anaemia and its consequences
in school children [3,10]. Studies in western Kenya found
the yearly cost of school-based IPT to be US$ 3.17 per
child [18] (Unless otherwise stated costs are adjusted to
US$ 2010 using national CPI). Notwithstanding inflation-
ary differences, the yearly cost of three rounds of IST at
US$ 18.72 per child is considerably higher than IPT. It
should be noted however, that the low cost of IPT hinges
on the ability to use SP or amodiaquine, which is no
longer possible in Kenya due to changes in national drug
policy withdrawing SP and amodiaquine monotherapy.
The ACT dihydroartemisinin-piperaquine (DP) has been
considered as an alternative for IPT in school children
[11], but would increase IPT costs [18]. The cost of IPT
for children (IPTc) aged between 1 and 5 years in Ghana
is estimated to be US$ 11.38 to US$ 14.79 [19] while a
comparison of strategies for delivering IPTc in the Gam-
bia estimated costs of US$ 3.85 and US$ 1.81 if delivered
by village health workers or reproductive and child health
trekking teams respectively [25]. This illustrates the
opportunities for cost reduction depending on delivery
strategy and highlights the potential difference in cost
between settings. Multi-site studies of IPT for infants
(IPTi) and for insecticide-treated bed net (ITN) distribu-
tion found respective yearly costs to be in the region of
US$ 1.36 to US$ 4.03 per child (US$ 2007) [26] and US$
1.38 and US$ 1.90 per child (US$ 2005) [27]. Studies are
also beginning to consider screening strategies for target-
ing asymptomatic malaria infection in the wider commu-
nity [28,29], although estimates of cost are not yet
available.
The sensitivity analysis provides an indication of how
the costs of IST may be reduced in the future. A variety of
malaria RDTs are currently available, but have varying
diagnostic performance and any cost savings in using dif-
ferent RDTs or an alternative diagnostic tool will need to
be balanced against performance. In the current study, the
cheaper RDT considered in the sensitivity analysis per-
forms slightly better than the trial RDT according to stu-
dies by the World Health Organization [30]. RDT
diagnosis performs similarly to or even better than routine
microscopy in health centres [31], although a lower mean
parasite density in asymptomatic infection may affect diag-
nostic performance. A study of school children with and
without fever in Benin found that while PCR diagnosis led
to a considerable increase in identified Plasmodium infec-
tion compared to microscopy or RDT, there was little or
no clinical benefit in treating sub-microscopic infection
[32]. Moreover, the costs of screening programmes using
microscopy or PCR diagnosis would likely be prohibitively
expensive. While cost-effectiveness of RDTs compared to
microscopy in health centres depends on the local setting
[33-36], the logistical disadvantage of microscopy as
a mobile diagnostic tool means it is unlikely to be cost-
effective for school-based IST.
The change to unsupervised treatment is justified on (i)
findings from previous clinical trials indicating that super-
vised treatment and unsupervised treatment are equivalent
in terms of efficacy [37,38] and (ii) that national guidelines
permit unsupervised treatment [39]. In addition to the
likely reduction in health worker personnel time on imple-
mentation, there may be scope for teachers to assist or
even lead screening. Studies in Zambia and the Demo-
cratic Republic of Congo have shown that RDTs can be
used effectively by non-medical personnel [40-42]. The
wider regional or national roll out of IST may result in
reduced RDT cost from bulk purchasing and improved
Figure 2 The relationship between the cost of school-based
intermittent screening and the prevalence of Plasmodium
falciparum in school children.
Figure 1 Tornado diagram of the percentage change in the
cost of intermittent screening in Kenyan schools in relation to
variation in component costs.
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efficiency from familiarity with the intervention. However,
as coverage expands to include those in more remote
areas, increased transport and therefore personnel time
may increase marginal cost. In addition, integration with
other school-based or community health programmes
provides further potential cost reduction through econo-
mies of scope. For example, school health programmes
currently provide children with de-worming and micronu-
trient supplementation [43]. The UNICEF led Child
Health Day programme can cost-effectively deliver multi-
ple health services to younger children [44] and bed net
distribution has been successfully integrated with routine
or campaign vaccination strategies [45]. IST implementa-
tion would need to be tailored to the epidemiological con-
text and take into account infrastructural capacity and
local geography. The cost, and ultimately cost-effective-
ness, will crucially depend on the prevalence of Plasmo-
dium infection, with overall costs decreasing with
decreasing prevalence but costs per child treated increas-
ing exponentially. However, this does not incorporate
potentially crucial cost savings associated with reducing
malaria transmission. That is, this strategy may indeed be
cost-effective at low to moderate prevalence if elimination,
or even reduction in transmission, is achieved.
There are certain limitations associated with economic
evaluations of randomized trials. In this case, the inter-
vention is designed with the trial objectives in mind and
not maximisation of cost-effectiveness, for example only
two classes per school were screened. In the base case
scenario all research only costs were removed but inter-
vention alterations were not modelled. The intention is
to maximize the level certainty in the base case estimate,
providing a solid estimate of cost from which to model
variation in setting or intervention design. Findings can
be generalized for settings with similar social, economic
and epidemiological conditions, such as Western or
Nyanza provinces [16]. Although specific figures will
change, options for cost reduction, issues around scale-
up and discussion of consequences are likely to remain
relevant. A degree of socio-economic, epidemiological
and environmental consistency is assumed and the analy-
sis does not account for significant exogenous variation.
In particular, it is assumed that the prevalence of malaria
remains constant year on year. It is noted that this is
unlikely to be the case in the study setting since trans-
mission is currently in decline [46].
In order to set the context of IST cost, the likely conse-
quences of IST are identified through consideration of the
trial outcomes and a review of the relevant literature
(Table 5). The aetiology of anaemia and its interaction
with malaria is complex but treating asymptomatic Plas-
modium infection using IPT has been found to reduce
anaemia by 48% in school children in western Kenya [3]
and 47-56% in children under five years of age in Mali and
Burkina Faso [47,48]. Although IST targets asymptomatic
infection there is likely to be an impact on the incidence
of clinical malaria through the reduction of superinfection
[49], whereby infection from an initial mosquito bite has
not cleared before a second infectious bite occurs. There
may also be a prophylactic effect of AL against new infec-
tion [50], an effect likely to vary according to drug choice.
In addition to the benefits for individuals receiving IST,
there may be effects on the wider community. In endemic
regions, individuals with chronic asymptomatic infection,
so-called asymptomatic carriers, are thought to represent
a significant reservoir of Plasmodium transmission and
treatment of such carriers can help reduce overall trans-
mission in the community [51-53]. Mathematical model-
ling of community-based screening and treatment and,
separately, of IPT in school children highlight the potential
for reducing malaria transmission in this way [12,54].
Further to these effects, school-level estimates of infection
prevalence derived from IST can help inform surveillance
of malaria transmission [55], a key resource in disease con-
trol. Finally, by targeting asymptomatic infection, IST
exposes a new section of the parasite population to an
anti-malarial resistance selection pressure. Yeung et al
describe the benefit of asymptomatic Plasmodium infec-
tions in suppressing the spread of drug resistance [56].
With regard to impact on malaria transmission, Kern
et al [54] found that intermittent community screening
campaigns using RDTs followed by treatment of asympto-
matic carriers has greatest impact in areas of high trans-
mission but that the rate of infection returned to its
normal level in the subsequent year, unless the interven-
tion was repeated, highlighting the potential of commu-
nity-based IST in reducing malaria transmission. In areas
of low transmission, the reduction in infection was sus-
tained for over three years following a single round of
intervention. The impact of screening and treating only
school children on the overall level of transmission in the
wider community remains to be established, but Aguas et
al find that IPT in school children has the potential to
reduce transmission particularly in areas of low or moder-
ate endemicity [12]. Kern et al also found that screening
campaigns scheduled in close succession (monthly inter-
vals) at the start of the dry season had the greatest impact
on the success of the intervention. Such findings have rele-
vance for the optimal delivery of school-based IST.
In addition to the impact on health and malaria con-
trol, school-based IST has the potential to improve edu-
cation and reduce household costs. Malaria is considered
to impact children’s educational achievement through
reduced school attendance due to illness and through
impaired concentration and cognition [3-7]. Recent work
by Chuma et al estimated the average cost to the house-
hold per episode of malaria in the study districts, Kwale
and Msambweni, to be US$ 2.52 [57] [Jane Chuma,
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personal communication]. The above breadth of potential
consequences of school-based IST necessitates that a
broad perspective to economic evaluation is adopted. A
possible approach is cost-consequence analysis (CCA), a
framework which presents, but does not aggregate, multi-
ple outcomes. Coast et al [58] and Williams et al [59]
support CCA as a clear and comprehensive approach to
economic evaluation whilst Weatherley et al [60] recom-
mend a CCA framework be used in the evaluation of
intersectoral costs and consequences.
Conclusions
This analysis shows that in the current setting IST in
schools is a relatively expensive intervention, primarily due
to the RDT costs and the follow-up visits to observe treat-
ment on day 2 and 3. However, many of the costs repre-
sent redeployment of existing resources and future
alteration in the design of the intervention can reduce
costs by 40%. Future research will evaluate impact of IST
in schools and how this might vary in different transmis-
sion and operational settings.
Additional material
Additional file 1: Unit Costs. A list of ingredient unit costs and relevant
data collected for this evaluation.
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